These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34127852)

  • 1. Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.
    Saxena AR; Gorman DN; Esquejo RM; Bergman A; Chidsey K; Buckeridge C; Griffith DA; Kim AM
    Nat Med; 2021 Jun; 27(6):1079-1087. PubMed ID: 34127852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
    Saxena AR; Frias JP; Gorman DN; Lopez RN; Andrawis N; Tsamandouras N; Birnbaum MJ
    Diabetes Obes Metab; 2023 Oct; 25(10):2805-2814. PubMed ID: 37311722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.
    Ono R; Furihata K; Ichikawa Y; Nakazuru Y; Bergman A; Gorman DN; Saxena AR
    Diabetes Obes Metab; 2023 Mar; 25(3):805-814. PubMed ID: 36433713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Saxena AR; Frias JP; Brown LS; Gorman DN; Vasas S; Tsamandouras N; Birnbaum MJ
    JAMA Netw Open; 2023 May; 6(5):e2314493. PubMed ID: 37213102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies.
    Buckeridge C; Tsamandouras N; Carvajal-Gonzalez S; Brown LS; Hernandez-Illas M; Saxena AR
    Diabetes Obes Metab; 2024 Aug; 26(8):3155-3166. PubMed ID: 38751362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
    Tillner J; Posch MG; Wagner F; Teichert L; Hijazi Y; Einig C; Keil S; Haack T; Wagner M; Bossart M; Larsen PJ
    Diabetes Obes Metab; 2019 Jan; 21(1):120-128. PubMed ID: 30091218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel approach to exploit Small-Molecule glucagon-like Peptide-1 receptor agonists with high potency.
    Wang X; Yun Y; Chen L; Guo S; Niu B; Fang J; Yuan Q; Shen J; Xie X; Wang K
    Bioorg Med Chem; 2024 Jun; 107():117761. PubMed ID: 38795571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.
    Karakasis P; Patoulias D; Pamporis K; Stachteas P; Bougioukas KI; Klisic A; Fragakis N; Rizzo M
    Metabolism; 2023 Dec; 149():155710. PubMed ID: 37852529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.
    Schmitt C; Portron A; Jadidi S; Sarkar N; DiMarchi R
    Diabetes Obes Metab; 2017 Oct; 19(10):1436-1445. PubMed ID: 28730694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes.
    Fediuk DJ; Gorman DN; Stoddard SA; Zhang Y; Ogden AG; Winton JA; Saxena AR
    J Clin Pharmacol; 2024 Apr; 64(4):449-460. PubMed ID: 37840155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.
    Jungnik A; Arrubla Martinez J; Plum-Mörschel L; Kapitza C; Lamers D; Thamer C; Schölch C; Desch M; Hennige AM
    Diabetes Obes Metab; 2023 Apr; 25(4):1011-1023. PubMed ID: 36527386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Novel 5,6-Dihydro-1,2,4-triazine Derivatives as Efficacious Glucagon-Like Peptide-1 Receptor Agonists.
    Chen L; Yun Y; Guo S; Wang X; Xiong M; Zhao T; Xu T; Shen J; Xie X; Wang K
    J Med Chem; 2023 Jun; 66(12):7988-8010. PubMed ID: 37286364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
    Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
    Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor.
    Griffith DA; Edmonds DJ; Fortin JP; Kalgutkar AS; Kuzmiski JB; Loria PM; Saxena AR; Bagley SW; Buckeridge C; Curto JM; Derksen DR; Dias JM; Griffor MC; Han S; Jackson VM; Landis MS; Lettiere D; Limberakis C; Liu Y; Mathiowetz AM; Patel JC; Piotrowski DW; Price DA; Ruggeri RB; Tess DA
    J Med Chem; 2022 Jun; 65(12):8208-8226. PubMed ID: 35647711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.